Production (Stage)
Lixte Biotechnology Holdings, Inc.
LIXT
$1.33
-$0.0502-3.64%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -32.25% | -32.10% | -30.03% | -28.99% | -22.00% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -29.32% | -29.81% | -30.04% | -34.55% | -22.24% |
| Operating Income | 29.32% | 29.81% | 30.04% | 34.55% | 22.24% |
| Income Before Tax | 29.13% | 29.51% | 29.65% | 34.37% | 22.12% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 29.13% | 29.51% | 29.65% | 34.37% | 22.12% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 29.13% | 29.51% | 29.65% | 34.37% | 22.12% |
| EBIT | 29.32% | 29.81% | 30.04% | 34.55% | 22.24% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 39.16% | 42.49% | 46.02% | 50.40% | 34.61% |
| Normalized Basic EPS | 39.16% | 42.49% | 46.01% | 50.39% | 34.60% |
| EPS Diluted | 39.16% | 42.49% | 46.02% | 50.40% | 34.61% |
| Normalized Diluted EPS | 39.16% | 42.49% | 46.01% | 50.39% | 34.60% |
| Average Basic Shares Outstanding | 11.84% | 17.47% | 27.28% | 32.50% | 24.61% |
| Average Diluted Shares Outstanding | 11.84% | 17.47% | 27.28% | 32.50% | 24.61% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |